- Home
- BBIO vs ESNT Comparison
BBIO vs ESNT Comparison
Compare BBIO & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ESNT
- Stock Information
- Founded
- BBIO 2015
- ESNT 2008
- Country
- BBIO United States
- ESNT Bermuda
- Employees
- BBIO N/A
- ESNT N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ESNT Property-Casualty Insurers
- Sector
- BBIO Health Care
- ESNT Finance
- Exchange
- BBIO Nasdaq
- ESNT Nasdaq
- Market Cap
- BBIO 8.0B
- ESNT N/A
- IPO Year
- BBIO 2019
- ESNT 2013
- Fundamental
- Price
- BBIO $46.47
- ESNT $55.99
- Analyst Decision
- BBIO Strong Buy
- ESNT Buy
- Analyst Count
- BBIO 14
- ESNT 7
- Target Price
- BBIO $60.21
- ESNT $63.71
- AVG Volume (30 Days)
- BBIO 3.3M
- ESNT 741.5K
- Earning Date
- BBIO 07-31-2025
- ESNT 08-01-2025
- Dividend Yield
- BBIO N/A
- ESNT 2.21%
- EPS Growth
- BBIO N/A
- ESNT 3.49
- EPS
- BBIO N/A
- ESNT 6.84
- Revenue
- BBIO $127,415,000.00
- ESNT $1,262,105,000.00
- Revenue This Year
- BBIO $107.34
- ESNT $5.40
- Revenue Next Year
- BBIO $49.48
- ESNT $3.66
- P/E Ratio
- BBIO N/A
- ESNT $8.19
- Revenue Growth
- BBIO N/A
- ESNT 9.57
- 52 Week Low
- BBIO $21.72
- ESNT $51.61
- 52 Week High
- BBIO $46.80
- ESNT $65.34
- Technical
- Relative Strength Index (RSI)
- BBIO 71.64
- ESNT 34.11
- Support Level
- BBIO $41.80
- ESNT $60.34
- Resistance Level
- BBIO $46.80
- ESNT $61.94
- Average True Range (ATR)
- BBIO 1.44
- ESNT 1.06
- MACD
- BBIO 0.09
- ESNT -0.55
- Stochastic Oscillator
- BBIO 94.00
- ESNT 2.90
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.